Cardiovascular Diabetology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3590, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2112, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=528, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2023-11-24 ms6000000946453986 来自山东省

偏重的研究方向：血脂;糖尿病
经验分享：有没有被接受的基础研究文章啊

60 0

[GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3590, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2112, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=528, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2023-10-10 ms8000000183026287 来自德国

10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。

89 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3590, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2112, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=528, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2022-01-16 123zz123

偏重的研究方向：临床队列
经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗

3590 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3590, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2112, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=528, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2023-06-25 ms8000001858743317 来自北京

有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高

179 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3590, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2112, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=528, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2023-04-12 ms8000001858743317 来自北京

请问大家初始技术审查大概持续多久

179 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3590, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2112, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=528, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2023-03-28 123d2a9fm15暂无昵称来自湖南省

想请问已投过的大神们，peer review 的状态是送审了吗

228 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3590, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2112, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=528, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2022-05-27 138*****882<手机用户>9442

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：糖尿病
经验分享：想问一下从接受到见刊再到sci收录大概要多长时间

2112 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3590, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2112, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=528, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2023-03-16 ms5000001279026069 来自福建省

偏重的研究方向：心血管;主动脉夹层
经验分享：想问下大家，不是做糖尿病可以投吗

228 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3590, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2112, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=528, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2023-02-07 jaimewang 来自山西省

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：内分泌
经验分享：希望今年IF能破10啊

221 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3590, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2112, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=528, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2022-11-10 木帆

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：心血管;糖尿病
经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高

528 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

平台业务解决方案

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务